Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2017 - 2023)

Lineage Cell Therapeutics (LCTX) has 5 years of Return on Invested Capital data on record, last reported at 0.35% in Q4 2023.

  • For Q4 2023, Return on Invested Capital fell 16.0% year-over-year to 0.35%; the TTM value through Dec 2023 reached 0.35%, down 16.0%, while the annual FY2025 figure was 0.21%, N/A changed from the prior year.
  • Return on Invested Capital reached 0.35% in Q4 2023 per LCTX's latest filing, up from 0.36% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.17% in Q1 2023 and bottomed at 0.38% in Q3 2019.
  • Average Return on Invested Capital over 3 years is 0.28%, with a median of 0.3% recorded in 2019.
  • The widest YoY moves for Return on Invested Capital: up -16bps in 2023, down -19bps in 2023.
  • A 3-year view of Return on Invested Capital shows it stood at 0.21% in 2019, then rose by 9bps to 0.19% in 2022, then tumbled by -84bps to 0.35% in 2023.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.35% in Q4 2023, 0.36% in Q3 2023, and 0.34% in Q2 2023.